Bionomics Investor Presentation Deck
✓ Emerging Regulatory Landscape & Unmet Need
Benzodiazepines prescribed off-label have
significant side effects of sedation, cognitive
impairment and potential for addiction
●
●
BNC210's Rapid Onset of Action is Well-Positioned for Social Anxiety Disorder
●
Growing unmet need based on improving
awareness and evolving regulatory dynamics
FDA precedent on simplified public speaking
challenge endpoint for acute anxiety reduction
vs. placebo*
Bionomics
*Based on path of CNS peer proceeding with registrational Phase 3 endpoint
●
●
●
✓ Rapid Onset of Action with BNC210 Formulation
Clinically demonstrated potential for reducing anxiety in acute
treatment of GAD patients and following panic induction
Observed acute anxiolytic efficacy of BNC210 similar to
lorazepam without sedative properties and addiction liability
Formulation well-suited for acute dosing - Rapidly absorbed to
high concentrations within a short period of time
路
Maximum
concentrations
reached in
-45-105 min.
across the
dose range
Concentration ng/ml
6000-
5000-
4000-
3000-
2000-
1000-
0
2
T
4
6
Concentration versus Time
1200 mg tablet fasted
900 mg tablet fasted
8
10 12 14
Time (hours)
600 mg tablet fasted
300 mg tablet fasted
16
12
18 20 22 24View entire presentation